戻る Agenda
Post COVID: Sites Evolving Role in the Clinical Trial Ecosystem
Session Chair(s)
Cristin MacDonald, PhD
Vice President, Client Delivery
WCG Clinical, United States
Following COVID-19, there is a changing role for Sites in the decision-making framework for the selection, implementation, and use of various technologies for clinical trial execution. We will discuss how Sponsors, CROs and Sites can move forward.
Learning Objective : Review the rapid response working group findings as it related to site execution and monitoring during the COVID-pandemic; Discuss how COVID-19 impacted traditional clinical trial execution decision making from dictating to sites how to conduct the research, to including/listening to sites for appropriate next steps; Identify how technology adoption in clinical trial execution will be decided upon.
Speaker(s)
Panelist
Greg Tuyteleers
Janssen, Belgium
Global Operations Head Managed Access and Global Lead Decentralized Trials
Panelist
Liz Rogers, MSc
Pfizer , United States
Head of Global Site and Study Operations
Panelist
Andy Lee, MA
Merck & Co., Inc., United States
Senior Vice President, Head of Global Clinical Trial Operations
Panelist
Sandy Smith
WCG , United States
Senior Vice President, Clinical Solutions and Strategic Partnerships